Germany-based Axplora announced the investment of  €50 million ($51.8 million) in its Mourenx site in Southwest France. Axplora specializes in large-scale API industrial chemistry and chromatography with a focus on cardiovascular and metabolic diseases.

总部位于德国的Axplora宣布在其位于法国西南部的Mourenx工厂投资5000万欧元（5180万美元）。Axplora专注于大规模API工业化学和色谱分析，专注于心血管和代谢疾病。

By upgrading Mourenx’s infrastructure and capabilities, Axplora expects to strengthen its position in peptide purification in a biologics environment and support the development of next-generation therapies, including GLP-1 drugs that target diabetes and obesity, which represent some of society’s most urgent health challenges, according to Arul Ramadurai, chief commercial officer of Axplora..

Axplora首席商务官Arul Ramadurai表示，通过升级Mourenx的基础设施和能力，Axplora有望加强其在生物制剂环境中肽纯化的地位，并支持下一代疗法的开发，包括针对糖尿病和肥胖症的GLP-1药物，这代表了社会最紧迫的健康挑战。。

“GLP-1 therapies represent a paradigm shift in medicine, offering targeted therapies for complex diseases with unprecedented efficacy and tolerability,” continued Ramadurai.

“GLP-1疗法代表了医学的范式转变，为复杂疾病提供了前所未有的疗效和耐受性的靶向治疗，”Ramadurai继续说道。

Construction and infrastructure development will begin immediately, with first supplies of GLP-1 therapies expected in 2026. Axplora operates nine API manufacturing sites across Europe and India, with the goal of providing multi-site capacity to partners worldwide.

建设和基础设施开发将立即开始，预计2026年将首次供应GLP-1疗法。Axplora在欧洲和印度运营着9个API生产基地，目标是为全球合作伙伴提供多基地能力。

News

新闻

Biological therapy

生物疗法

Cardiovascular diseases

心血管疾病

Diabetes

糖尿病

Drug development (Pharmacology)

药物开发（药理学）

Metabolic disorders

代谢紊乱

Obesity

肥胖

Peptides

肽

Axplora

探索